The cell cycle-related and expression-elevated protein in tumor (CREPT) is overexpressed in several human malignancies. However, the clinical relevance of CREPT expression and its biological role in non-small-cell lung cancer (NSCLC) remains unclear. In this study, we detected the expression of CREPT in both NSCLC tissues -
lung cancer (NSCLC, approximately 85% of cases) and small-cell lung cancer (SCLC, approximately 15% of cases). 2 Even though several diagnostic techniques and treatments have been developed, 3, 4 approximately 40% of NSCLC patients are first diagnosed at an advanced stage. 5 The 5-year overall survival (OS) rate of these patients was less than 18%. 6, 7 Therefore, it is imperative to identify the relevant genes associated with the prognosis of NSCLC and provide individualization treatment.
Cell cycle-related and expression-elevated protein in tumor (CREPT) (GenBank NM_021215), a novel gene also called RPRD1B
or C20ORF77, is involved in the development and prognosis of various tumors, including liver cancer, breast cancer, retroperitoneal leiomyosarcoma, and endometrial cancer. [8] [9] [10] [11] [12] Lu et al 10 have
shown that CREPT enhances the expression of CyclinD1 by promoting the formation of a chromatin loop, by interacting with RNA polymerase II. Previous studies have shown that CREPT expression is correlated with tumor differentiation, Dukes' stage, and metastasis in colorectal tumors. 12 She et al 13 found that
CREPT is elevated in retroperitoneal leiomyosarcoma tissues and plays important roles in the progression of retroperitoneal leiomyosarcoma. In our previous study, CREPT silencing significantly inhibited the proliferation and migration of NSCLC cell lines. 8 However, the relationship between overexpression of CREPT and prognosis in NSCLC remains unknown. In this study, the expression of CREPT in 271 NSCLC tissues and corresponding adjacent non-tumor tissues was detected by immunohistochemical staining, and the correlation between CREPT expression and clinicopathologic features were analyzed. Furthermore, CREPT was overexpressed in Calu-1 cells and its biological function was investigated both in vitro and in vivo.
| MATERIALS AND METHODS

| Patients and tissue samples
We 
| Cell culture
Human NSCLC cell lines (H520, A549, H838, Spc-A-1, and Calu-1)
were purchased from ATCC (Manassas, VA, USA). The cells were cultured in RPMI-1640 (Gibco, USA) containing 10% FBS (Gibco) and 1% penicillin-streptomycin. Cells were cultured at 37°C in a humidified atmosphere of 5% CO 2 .
| Immunohistochemistry
The paraffin-embedded tissues were sliced into 3-lm sections and deparaffinized, then the slides were boiled in 10 mmol/L citrate buffer for antigen retrieval and blocked with 10% goat serum. The slides were then incubated with primary anti-CREPT (1:200; GeneTex) or anti-Ki-67 (1:200; GeneTex) antibodies overnight. The same concentration of antigen-specific antibody (Kangwei) was used as negative control. After washing with PBS, the tissue sections were incubated with EnVision HRP (Kangwei, China) as the secondary antibody.
Finally, the DAB Elite kit (Zhongshan, China) was used for chemiluminescence analysis. All stained sections were examined by two independent investigators who were blinded to the clinical features and outcomes. The immunohistochemical (IHC) staining scores were based on the following criteria: (i) the percentage of positive cells (0, ≤5%; 1, 6%-25%; 2, 26%-50%; 3, 51%-75%; and 4, >75%); (ii) the staining intensity (0, no color; 1, yellow; 2, brown; and 3, tan); and (iii) the two grades were multiplied together and specimens were assigned to one of four levels: 0, negative (À); 1-4, weakly positive (+); 5-8, moderately positive (++); and 9-12, strongly positive (+++). 8, 15 To investigate the correlation of protein expression, (À) and (+) were considered as low expression, and (++) and (+++) were considered as high expression. 
| Western blot analysis
| Wound healing assay
Cell migration was assessed by a wound healing assay. Briefly, cells (5 9 10 5 cells/well) stably transfected with CREPT or empty vector were selected using G418 and then cultured in 6-well plates until confluent. The cell monolayer was scraped in a straight line and washed with PBS, and then images were captured at 0, 12, and 24 hours under a 109 objective (Olympus, Japan). The migration distance was measured and assessed using ImageJ software at six random optical fields on each filter to evaluate cell migration. The percentage change in migration was determined by comparison of the differences in wound width. The experiments were carried out in duplicate.
| Transwell migration and invasion assay
The invasion and migration ability of the cells were examined using Transwell assay with a 24-well Transwell chamber ( 
| In vivo mouse models
All experimental procedures were approved by the Animal Ethics 
| Statistical analysis
Data are expressed as values of mean AE SD. Results were evaluated using the t-test. Associations between two groups were evaluated using the v 2 -test and Spearman's correlation analysis. Survival curves were examined using the Kaplan-Meier method, and the significance of the difference was evaluated using the log-rank test. Univariate and multivariate survival analyses were undertaken using the Cox hazard regression model. All analyses were carried out with SPSS 19.0 software (SPSS, Chicago, IL, USA). P < .05 was considered to be statistically significant. 
| Correlation between CREPT expression and clinicopathologic features
In order to determine the clinical significance of CREPT in NSCLC, the relationship between CREPT expression and clinicopathologic characteristics was investigated ( Table 1 ). The CREPT expression was significantly associated with clinical stage (P = .025), tumor differentiation (P = .000), and lymphatic metastasis (P = .020). There was a strong correlation between CREPT expression and Ki-67 proliferation index (P = .002). However, no significant relationship was observed between CREPT expression and age (P = .380), gender (P = .627), smoking history (P = .894), tumor size (P = .253), pathology (P = .638), or tumor location (P = .121).
| Overexpression of CREPT promotes cell proliferation by inducing cells to enter G1 phase from S phase
To investigate the role of CREPT on the progression of NSCLC, pcDNA3.1-CREPT plasmid was adopted to transfect the Calu-1 cell line and G418 screening to obtain stable cell lines highly expressing CREPT. We confirmed the efficacy of CREPT overexpression using clearly increased compared to the control group ( Figure 4B,C) . The expression of CREPT in the pcDNA3.1-CREPT group was significantly higher than that in tumors treated with pcDNA3.1 (Figure 4D) . To determine the effect of CREPT on proliferation, immunohistochemical staining showed that the proliferation marker Ki-67 was stronger in the pcDNA3.1-CREPT group ( Figure 4D ). In addition, the levels of Ki-67 mRNA and protein in pcDNA3.1-CREPT tumors were significantly higher than in the control group (Figure 4E) . These results confirm that the overexpression of CREPT significantly promotes tumor growth in vivo. | 1015
Meier analysis showed that patients with higher CREPT expression revealed a significantly shorter OS (log-rank test, P = .01; Figure 5A ) and RFS (P = .006; Figure 5B ) compared to patients with lower CREPT expression.
In order to investigate the correlation of protein expression and patients' clinical outcomes, the median CREPT protein expression was used as the cut-off point to divide high expression and low expression groups for NSCLC patients. In order to assess the relationship between CREPT expression and the clinical outcomes of NSCLC patients according to the different pathology, the patients were divided into the squamous cell carcinoma (SCC) and adenocarcinoma (ADC) groups. The median survival time of SCC patients with high CREPT expression was 31 months (95% confidence interval
[CI], 21-41 months) and low CREPT expression was 53 months (95% CI, 38-68 months). The result showed that the group with high CREPT expression had a worse prognosis than those in the low CREPT expression group in SCC patients (P = .03; Figure 5 ). However, there were no obvious significant difference in the survival rate with respect to CREPT expression among ADC patients (P = .3; Figure 5C ). A previous study showed that CREPT is associated with clinical stage, lymph node metastasis, and distant metastasis in breast cancer patients. 9 She et al. also revealed that the expression of CREPT may be closely related to histological grade in retroperitoneal leiomyosarcoma patients. 13 The present study clearly indicated that CREPT expression is significantly correlated with clinical stage, tumor differentiation, and lymphatic metastasis in NSCLC patients. These results indicated that CREPT could play a significant role in NSCLC development and
progression.
An earlier study showed that CREPT expression was correlated with poor prognosis in stomach cancer and retroperitoneal leiomyosarcoma patients. 10, 13 Our previous study proved that CREPT overexpression was significantly correlated with shorter survival in colorectal cancer patients. 12 In the current investigation, the survival analysis revealed that NSCLC patients with higher CREPT expression levels showed significantly shorter survival time compared to those with lower CREPT expression levels. Overexpression of CREPT was related to the malignant behavior of tumors during NSCLC progression. We also evaluated the prognostic significance of CREPT expression in different clinical features of NSCLC patients.
Adenocarcinoma is associated with a poorer prognosis and a greater probability of distant recurrence compared with SCC. 16 Gene expression profiles are known to differ substantially between ADC and SCC, and each histological subtype has a different etiology, carcinogenesis, and clinicopathologic behavior. [17] [18] [19] [20] These studies revealed that the prognostic outcome might be different in SCC and ADC subgroups, which indicated that it is necessary to find an accurate prognostic marker. Based on our analysis, the expression level of CREPT is significantly associated with OS of SCC patients. Specifically, high CREPT expression was a much more significant survival factor for SCC patients than ADC patients. We speculated that CREPT is likely to represent a transformation factor associated with poor prognosis in the SCC development pathway. Considering the limitation of sample size, the differences in the role of CREPT carcinogenesis in SCC and ADC should be validated by further investigations.
We also investigated whether CREPT expression was associated with prognosis in NSCLC patients at different clinical stages. We noticed that the prognostic significance of CREPT expression was apparent in patients with advanced clinical stage, whereas the difference in the survival rate with respect to CREPT expression among patients with early stage was not significant. Further analysis suggested that lymph node metastasis patients with higher CREPT expression had a lower OS compared to those with lower CREPT expression; the difference was significant for lymph node-negative patients as well as lymph node-positive patients. A previous study has highlighted the size of the primary tumor as an independent prognostic factor for patients with NSCLC. 21 Zhang et al. found that tumor size is an independent prognostic factor, for early stage as well as node-positive and locally invasive disease. 22 We detected that CREPT was a much more significant survival factor for NSCLC patients with larger tumor size (diameter >5 cm) than those with smaller tumor size (diameter ≤5 cm). These findings suggested that the expression of CREPT was specifically more relevant to the survival of advanced staged SCC patients with large tumor size, which can be used as a precise prognostic marker for NSCLC patients.
In the univariate survival analysis, CREPT expression concomitant with TNM stages, tumor differentiation, and lymph node metastasis are all related with NSCLC patients' prognosis. More importantly, multivariate survival analysis revealed that CREPT expression (HR, 1.223; P = .013) was an independent prognostic factor, along with TNM stage (HR, 0.480; P = .001). We found that CREPT could serve as a potential independent biomarker to predict the prognosis of NSCLC patients.
In a previous study, we explored the biological effect of inhibiting CREPT on NSCLC cell proliferation in vitro. 8 These results have motivated us to further investigate the critical role of CREPT in NSCLC cell proliferation. Therefore, we overexpressed CREPT in 
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